|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib显示文摘 | Maria Reig Ferran Torres Carlos Rodriguez-Lope Alejandro Forner Neus LLarch Jordi Rimola Anna Darnell José Ríos Carmen Ayuso Jordi Bruix | 2014 | Journal of Hepatology2014，，： | 2 |
| 2 | Postprogression survival of patients with advanced hepatocellular carcinoma: Rationale for second‐line trial design显示文摘 | Maria Reig Jordi Rimola Ferran Torres Anna Darnell Carlos Rodriguez‐Lope Alejandro Forner Neus LLarch José Ríos Carmen Ayuso Jordi Bruix | 2013 | Hepatology2013，，6： | 2 |
| 3 | Management of HCC显示文摘 | Carlos Rodriguez de Lope Silvia Tremosini Alejandro Forner Maria Reig | 2012 | Journal of Hepatology2012，，： | 1 |
| 4 | Tumor biopsy and patient enrollment in clinical trials for advanced hepatocellular carcinoma显示文摘Tumor biopsies may help to reliably distinguish hepatocellular carcinoma(HCC) from other tumors, mostly cholangiocarcinoma as well as to identify the patient populations who most benefit from target-driven HCC treatments, in order to improve the success rate of experimental therapies. Clarifying tumor biology may also lead to identify biomarkers with prognostic role and/or enabling to predict response or resistance to therapies. Recently, clinical trials have more efficiently included biomarker endpoints and increasingly collected tumor tissue from enrolled patients. Due to their frail status and sometimes fast-progressing disease, the performance status of patients with HCC progressing on first-line therapy can deteriorate quickly, preventing their enrollment in clinical trials. However, the challenge of identifying the proper patient at the proper time can be overcome by periodic inter-department meetings involving the key specialists taking care of HCC patients, and solid networks between research centers and referring institutions. An early planned biopsy would also facilitate timely inclusion of patients in biology-driven clinical trials. Ultimately, institution of multidisciplinary teams can optimize treatment choice, biopsy timing, and quick enrollment of patients in clinical trials, before their performance status deteriorates. | Lorenza Rimassa Maria Reig Giovanni Abbadessa Markus Peck-Radosavljevic William Harris Vittorina Zagonel Davide Pastorelli Elena Rota Caremoli Camillo Porta Nevena Damjanov Hitendra Patel Bruno Daniele Maria Lamar Brian Schwartz Terri Goldberg Armando Santoro Jordi Bruix | 2017 | World Journal of Gastroenterology2017，23，13： | 1 |
| 5 | Non-invasive diagnosis of hepatocellular carcinoma ?2<ce:hsp sp='0.25'/>cm in cirrhosis. Diagnostic accuracy assessing fat, capsule and signal intensity at dynamic MRI显示文摘 | Jordi Rimola Alejandro Forner Silvia Tremosini Maria Reig Ramón Vilana Luis Bianchi Carlos Rodríguez-Lope Manel Solé Carmen Ayuso Jordi Bruix | 2012 | Journal of Hepatology2012，，6： | 1 |
| 6 | Newdrugs for the treatment of hepatocellular carcinoma 显示文摘 | Eveline Boucher Alejandro Forner Maria Reig | 2009 | Liver International2009，29，1： | 1 |
| 7 | Clinical decision making and research in hepatocellular carcinoma: Pivotal role of imaging techniques显示文摘 | Jordi Bruix Maria Reig Jordi Rimola Alejandro Forner Marta Burrel Ramón Vilana Carmen Ayuso | 2011 | Hepatology2011，，6： | 1 |
| 8 | Systemic Therapy for Hepatocellular Carcinoma: The Issue of Treatment Stage Migration and Registration of Progression Using the BCLC-Refined RECIST显示文摘 | Maria Reig Anna Darnell Alejandro Forner Jordi Rimola Carmen Ayuso Jordi Bruix | 2014 | Semin Liver Dis2014，，04： | 1 |
| 9 | Portal hypertension and the outcome of surgery for hepatocellular carcinoma in compensated cirrhosis: A systematic review and meta‐analysis显示文摘 | Annalisa Berzigotti Maria Reig Juan G. Abraldes Jaime Bosch Jordi Bruix | 2015 | Hepatology2015，，2： | 1 |
| 10 | Observatory science with eXTP显示文摘In this White Paper we present the potential of the enhanced X-ray Timing and Polarimetry(eXTP) mission for studies related to Observatory Science targets. These include flaring stars, supernova remnants, accreting white dwarfs, low and high mass X-ray binaries, radio quiet and radio loud active galactic nuclei, tidal disruption events, and gamma-ray bursts. eXTP will be excellently suited to study one common aspect of these objects: their often transient nature. Developed by an international Consortium led by the Institute of High Energy Physics of the Chinese Academy of Science, the eXTP mission is expected to be launched in the mid 2020s. | Jean J.M.in 't Zand Enrico Bozzo JinLu Qu Xiang-Dong Li Lorenzo Amati Yang Chen Immacolata Donnarumma Victor Doroshenko Stephen A.Drake Margarita Hernanz Peter A.Jenke Thomas J.Maccarone Simin Mahmoodifar Domitilla de Martino Alessandra De Rosa Elena M.Rossi Antonia Rowlinson Gloria Sala Giulia Stratta Thomas M.Tauris Joern Wilms XueFeng Wu Ping Zhou Iván Agudo Diego Altamirano Jean-Luc Atteia Nils A.andersson M.Cristina Baglio David R.Ballantyne Altan Baykal Ehud Behar Tomaso Belloni Sudip Bhattacharyya Stefano Bianchi Anna Bilous Pere Blay Joao Braga Sφren Brandt Edward F.Brown Niccolo Bucciantini Luciano Burderi Edward M.Cackett Riccardo Campana Sergio Campana Piergiorgio Casella Yuri Cavecchi Frank Chambers Liang Chen Yu-Peng Chen Jér?me Chenevez Maria Chernyakova ChiChuan Jin Riccardo Ciolfi Elisa Costantini Andrew Cumming Antonino D'Aì Zi-Gao Dai Filippo D'Ammando Massimiliano De Pasquale Nathalie Degenaar Melania Del Santo Valerio D'Elia Tiziana Di Salvo Gerry Doyle Maurizio Falanga XiLong Fan Robert D.Ferdman Marco Feroci Federico Fraschetti Duncan K.Galloway Angelo F.Gambino Poshak Gandhi MingYu Ge Bruce Gendre Ramandeep Gill Diego G?tz Christian Gouiffès Paola Grandi Jonathan Granot Manuel Güdel Alexander Heger Craig O.Heinke Jeroen Homan Rosario Iaria Kazushi Iwasawa Luca Izzo Long Ji Peter G.Jonker Jordi José Jelle S.Kaastra Emrah Kalemci Oleg Kargaltsev Nobuyuki Kawai Laurens Keek Stefanie Komossa Ingo Kreykenbohm Lucien Kuiper Devaky Kunneriath Gang Li En-Wei Liang Manuel Linares Francesco Longo FangJun Lu Alexander A.Lutovinov Denys Malyshev Julien Malzac Antonios Manousakis Ian McHardy Missagh Mehdipour YunPeng Men Mariano Méndez Roberto P.Mignani Romana Mikusincova M.Coleman Miller Giovanni Miniutti Christian Motch Joonas Nättilä Emanuele Nardini Torsten Neubert Paul T.O'Brien Mauro Orlandini Julian P.Osborne Luigi Pacciani Stéphane Paltani Maurizio Paolillo Iossif E.Papadakis Biswajit Paul Alberto Pellizzoni Uria Peretz Miguel A.Pérez Torres Emanuele Perinati Chanda Prescod-Weinstein Pablo Reig Alessandro Riggio Jerome Rodriguez Pablo Rodríguez-Gil Patrizia Romano Agata Rózańska Takanori Sakamoto Tuomo Salmi Ruben Salvaterra andrea Sanna andrea Santangelo Tuomas Savolainen Stéphane Schanne Hendrik Schatz LiJing Shao andy Shearer Steven N.Shore Ben W.Stappers Tod E.Strohmayer Valery F.Suleimanov Jirí Svoboda F.-K.Thielemann Francesco Tombesi Diego F.Torres Eleonora Torresi Sara Turriziani andrea Vacchi Stefano Vercellone Jacco Vink Jian-Min Wang JunFeng Wang Anna L.Watts ShanShan Weng Nevin N.Weinberg Peter J.Wheatley Rudy Wijnands Tyrone E.Woods Stan E.Woosley ShaoLin Xiong YuPeng Xu Zhen Yan George Younes WenFei Yu Feng Yuan Luca Zampieri Silvia Zane andrzej A.Zdziarski Shuang-Nan Zhang Shu Zhang Shuo Zhang Xiao Zhang Michael Zingale | 2019 | Science China(Physics,Mechanics & Astronomy)2019，62，2： | 0 |
| 11 | Polymorphism AGT2(rs4762)is involved in the development of dermatologic events:Proof-of-concept in hepatocellular carcinoma patients treated with sorafenib显示文摘BACKGROUND Dermatologic adverse events(DAEs)are associated with a better outcome in patients with hepatocellular carcinoma(HCC)irrespective of the therapeutic agent received.The exact mechanisms associated with the development of DAEs are unknown although several studies point to direct toxicity of tyrosine kinase inhibitors(TKIs)to the skin or an immune-mediated reaction triggered by the oncologic treatment.As is the case in other conditions,individual genetic variants may partially explain a higher risk of DAEs.AIM To evaluate the contribution of several gene variants to the risk of developing DAEs in HCC patients treated with TKIs.METHODS We first analyzed 27 single-nucleotide polymorphisms(SNPs)from 12 genes selected as potential predictors of adverse event(AE)development in HCC patients treated with sorafenib[Barcelona Clinic Liver Cancer 1(BCLC1)cohort].Three additional cohorts were analyzed for AGT1(rs699)and AGT2(rs4762)polymorphisms-initially identified as predictors of DAEs:BCLC2(n=79),Northern Italy(n=221)and Naples(n=69)cohorts,respectively.The relation between SNPs and DAEs and death were assessed by univariate and multivariate Cox regression models,and presented with hazard ratios and their 95%confidence intervals(95%CI).RESULTS The BCLC1 cohort showed that patients with arterial hypertension(AHT)(HR=1.61;P value=0.007)and/or AGT SNPs had an increased risk of DAEs.Thereafter,AGT2(rs4762)AA genotype was found to be linked to a statistically significant increased probability of DAEs(HR=5.97;P value=0.0201,AA vs GG)in the Northern Italy cohort by multivariate analysis adjusted for BCLC stage,ECOG-PS,diabetes and AHT.The value of this genetic marker was externally validated in the cohort combining the BCLC1,BCLC2 and Naples cohorts[HR=3.12(95%CI:1.2-8.14),P value=0.0199,AGT2(rs4762)AA vs AG genotype and HR=2.73(95%CI:1.18-6.32)P value=0.0188,AGT2(rs4762)AA vs GG genotype].None of the other gene variants tested were found to be associated with the risk of DAE development.CONCLUSION DAE development in HCC patients receiving TKIs could be explained by the AGT2(rs4762)gene variant.If validated in other anti-oncogenic treatments,it might be considered a good prognosis marker. | Víctor Sapena Massimo Iavarone Loreto Boix Floriana Facchetti Maria Guarino Marco Sanduzzi Zamparelli Alessandro Granito Esther Samper Mario Scartozzi Josep Corominas Giorgia Marisi Alba Díaz Andrea Casadei-Gardini Laura Gramantieri Pietro Lampertico Filomena Morisco Ferran Torres Jordi Bruix María Reig | 2022 | World Journal of Hepatology2022，14，7： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员